Clinical trials sponsored by Janssen Research & Development, LLC

Phase breakdown

Conditions studied

Recruiting trials led by Janssen Research & Development, LLC

• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
  NCT06663332 · Phase: Phase 3 · Ages: 3 Years and older · Sex: All (male and female) · 147 locations
• A Long-term Extension Study of PCI-32765 (Ibrutinib)
  NCT01804686 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 175 locations
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 401 locations
• A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia
  NCT07541261 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
  NCT05379595 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
  NCT06750094 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 251 locations
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT07227025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
  NCT06662786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 238 locations
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT05498428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
  NCT07230691 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 80 locations
• A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
  NCT07716098 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
  NCT07499232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
  NCT07220824 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
  NCT05923073 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 85 locations
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer
  NCT07524855 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 6 locations
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 370 locations
• A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
  NCT07082920 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 6 locations
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
  NCT07577843 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 142 locations
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07577856 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 170 locations
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
  NCT06095089 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
  NCT06663319 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
  NCT07107230 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
  NCT07746713 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 3 locations
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
  NCT07586202 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 249 locations
• A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
  NCT07319871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
  NCT05818683 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 152 locations
• A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
  NCT07582783 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
  NCT07615426 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 8 locations
• A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
  NCT07654751 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 3 locations
• A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
  NCT06807424 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 236 locations
• A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
  NCT07321873 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 73 locations
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 205 locations
• Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
  NCT06800313 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 18 locations

Common questions

How many trials is Janssen Research & Development, LLC recruiting for?

Janssen Research & Development, LLC is the lead sponsor of 35 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.